Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;54(2):217-218.
doi: 10.1111/apt.16458.

Letter: safety of immune checkpoint inhibitors in patients with pre-established microscopic colitis-a single-centre experience

Thomas W Fredrick  1 , Manuel B Braga Neto  2 , Guilherme P Ramos  2 , Sunanda Kane  2 , Darrell S Pardi  2 , Laura E Raffals  2
Affiliations
Comment

Letter: safety of immune checkpoint inhibitors in patients with pre-established microscopic colitis-a single-centre experience

Thomas W Fredrick et al. Aliment Pharmacol Ther. 2021 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021;53:374-382.
    1. Pardi DS. Diagnosis and management of microscopic colitis. Am J Gastroenterol. 2017;112:78-85.
    1. Miehlke S, Verhaegh B, Tontini GE, Madisch A, Langner C, Münch A. Microscopic colitis: pathophysiology and clinical management. Lancet Gastroenterol Hepatol. 2019;4:305-314.
    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
    1. Kröner PT, Mody K, Farraye FA. Immune checkpoint inhibitor-related luminal GI adverse events. Gastrointest Endosc. 2019;90:881-892.

MeSH terms

Substances